How it works, simply
It binds somatostatin receptors, reducing certain hormone signals.
What the evidence tells us
Tumor and hormone-control outcomes must be interpreted for the specific diagnosed condition.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
- Gallstones and changes in blood glucose are relevant risks.
- Gastrointestinal symptoms and reduced heart rate are described in the label.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Binds somatostatin receptors to suppress hormone release and tumor-associated signaling.
Sponsor or developer: Ipsen
Studied or labeled topics: Acromegaly, Neuroendocrine tumors
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- DailyMed: SOMATULINE DEPOT prescribing information ↗ · Regulator · Oct 17, 2024
Product labels and further research
These directories help locate records. They are not individual studies supporting every statement.
Readability updated October 10, 2026. Evidence review: October 10, 2026 (linked label: purpose and selected risks). A wording update is not a new clinical review.